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Abstract
Introduction. Idiopathic dilated cardiomyopathy is a disease of unknown aetiology, characterized by left ventricular systo-
lic dysfunction. Despite new diagnostic methods and pharmacological treatment, dilated cardiomyopathy still remains 
a major cause of morbidity and mortality. The aim of the study was to determine prognostic factors, efficacy of statin 
use, and clinical adverse events in patients with idiopathic dilated cardiomyopathy.
Material and methods. Ninety-five patients with idiopathic dilated cardiomyopathy (47 in the treated group and 48 in 
the control group) were randomized to receive add-on therapy with atorvastatin 20 mg daily. All patients underwent 
thorough clinical, electrocardiographic and echocardiographic evaluation at baseline and after 12 months of follow-up.
Results. During the 12 months of follow-up, 23 patients died (12 in the treated group and 11 in the control group). 
During the follow-up, the severity of heart failure symptoms (as measured by the NYHA functional class) decreased and 
the glomerular filtration rate increased in parallel to an improvement seen in several echocardiographic parameters.
Conclusions. Based on our study findings, statin use is not associated with a better prognosis in patients with idiopathic 
dilated cardiomyopathy. Risk stratification in this group of patients is possible on the basis of clinical, biochemical, and 
echocardiographic parameters.
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Introduction
Dilated cardiomyopathy (DCM) [1, 2] is a primary chronic 
myocardial disease manifesting with systolic dysfunction 
which is not due to pericardial disease, coronary artery 
disease, hypertension, congenital heart disease, or val-
vular heart disease [3]. The diagnosis of DCM requires 
excluding the above listed etiologic factors. In most cases, 
the cause is difficult to establish, and microscopy shows 
diffuse interstitial and perivascular myocardial fibrosis with 
partial involvement of the left ventricular subendocardial 
layer, with some focal necrosis and cellular infiltrates which 
usually are not the predominant histological findings [2]. 
A large variation of the cardiomyocyte size is notable, 
with atrophy of some cells and hypertrophy of others. No 
characteristic histologic findings of idiopathic DCM have 
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been identified in the research studies. It is known that in 
addition to a genetic predisposition, a major role is played 
by inflammatory processes and pathological apoptosis or 
programmed cell death [2, 4].
The natural history of DCM is varied and incompletely 
understood. Many patients may remain asymptomatic 
despite slowly progressing disease [5, 6]. Annual mortality 
in patients with the typical progression of heart failure 
resulting from DCM has been estimated at 11–13% [7].
The aim of the present study was to determine the 
effects of one-year atorvastatin treatment at the dose 
of 20 mg daily, and in particular the effect on the rate of 
clinical endpoints (death, readmission, and the need for 
cardiac transplantation) in patients with idiopathic DCM 
during one year of follow-up.
The study was a prospective, unblinded clinical trial with 
random assignment to the active treatment (atorvastatin 
20 mg).
Material and methods
Study group
The study included 95 patients (47 in the group receiving 
active treatment with atorvastatin 20 mg [ATOR(+)] and 48 
in the control group [ATOR(–)]) with the diagnosis of DCM 
who were under the care of the Chair and Department of 
Cardiology, Medical University of Łódź, and its cardiology 
clinic. All patients recruited in the study received written 
information about the study and gave a written informed 
consent for participation in the study. The study protocol 
was approved by the Bioethics Committee at the Medical 
University of Łódź (approval No. RNN/207/06/KE of No-
vember 28, 2006). All patients recruited into the study 
received medications recommended for the treatment of 
heart failure (according to the current Polish Cardiac Soci-
ety and the European Society of Cardiology guidelines). In 
addition to the drugs recommended for the treatment of 
heart failure, patients who were randomly assigned to the 
active treatment group also received atorvastatin 20 mg 
daily for one year. All patients underwent detailed clinical, 
electrocardiographic, and echocardiographic evaluation 
(using two-dimensional echocardiography and tissue Dop-
pler imaging) at baseline and at 12 months of follow-up.
Patients who were assigned to the active treatment 
group (n = 47) and the control group (n = 48) were sub-
jects with the diagnosis of DCM made in accordance to the 
current recommendations [5]:
 — ventricular dilation;
 — reduced global left ventricular systolic function as evi-
denced by the left ventricular ejection fraction (LVEF) 
below 35%;
 — no coronary lesions as evaluated by coronary angio-
graphy;
 — absence of other causes of ventricular dysfunction 
including hypertension, valvular disease, and ischemic 
heart disease.
All patients included into the study fulfilled the following 
criteria:
 — diagnosis of idiopathic DCM according to the World 
Health Organization (WHO) criteria, with exclusion of 
secondary cardiomyopathy;
 — disease duration of up to 3 months or increase in the 
severity of heart failure by at least one New York Heart 
Association (NYHA) functional class;
 — full drug therapy according to the current standards of 
care and recommendations of the Polish Cardiac Society;
 — written consent for participation in the study, given 
after the patients were provided written information 
and received extensive answers to any questions they 
might have had;
 — age above 18 years.
Study protocol
The study protocol included the following procedures at 
baseline and at 12 months:
 — medical history;
 — physical examination with blood pressure measure-
ment;
 — blood sampling (10 mL) from an antecubital vein for 
complete blood count and biochemical testing;
 — resting electrocardiogram;
 — 6-minute walking test (6MWT) to evaluate exercise 
tolerance;
 — conventional Doppler echocardiography to evaluated 
global and regional wall motion and diastolic function;
 — tissue Doppler imaging to evaluate myocardial velocity 
and strain.
The patients were followed up for one year (mean 
12.6 ± 3.9 months) to identify the occurrence of clinical 
endpoints (evaluated separately and as a combined end-
point) (Table 1) including:
 — all-cause mortality;
 — need to implant a pacemaker;
 — patient enlisting to the cardiac transplantation program,
 — worsening of heart failure symptoms (by at least one 
NYHA class) or the 6MWT result (walking distance 
reduction by more than 10%);
 — combined clinical endpoint defined as the occurrence 
of at least one of the above listed endpoints.
Statistical analysis
Descriptive statistics and group comparisons
Quantitative descriptive data were reported as mean values 
± standard deviation or median (minimum, maximum) in 
case of non-normally distributed variables. Normal distri-
bution of the variables was verified using the Kolmogo-
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rov-Smirnov test (for large samples) or the Shapiro-Wilk 
test (for small samples). If a variable was non-normally 
distributed, median values were compared using the non-
parametric Mann-Whitney U test, and the Student t test 
was used for normally distributed variables. Categorical 
data were compared using the chi-square Pearson test. 
Differences were considered significant at P < 0.05.
Treatment outcomes
In univariate analysis, the patients were divided into those 
with or without an endpoint, and all variables were com-
pared between the two groups. Quantitative variables were 
compared using the Student t test for paired samples or the 
nonparametric Mann-Whitney U test. Categorical data were 
compared using the Fisher exact test. Receiver-operating 
characteristics (ROC) curves were plotted for quantitative 
variables and areas under the curve (AUC) were calculated 
as the measure of the usefulness of a given variable to 
predict endpoint occurrence. For each ROC curve, cut-off 
values were determined and the sensitivity and specificity 
values were calculated for the endpoint prediction. Finally, 
odds ratios (OR) were calculated as the measure of the 
increase in the risk of an endpoint.
Multivariate logistic regression analysis included only 
those variables which were significant in the univariate 
analysis.
Results
Group characteristics  
— functional parameters
The study groups did not differ in regard to major clinical 
and demographic parameters. Comparison of the medi-
cal history data is shown in Tables 2 and 3. Trends were 
noted for more frequent occurrence of familial DCM in the 
atorvastatin group and of impaired glucose tolerance in 
Table 2. Medical history data collected using a questionnaire (a trend for more frequent occurrence of familial DCM in the active group, 
no significant differences between the groups)
Variable ATOR(+) ATOR(–) P
Age [years] 51.7 ± 12.3 (25–76) 53.7 ± 11.8 (24–76) 0.42
Gender [male/female] 40/7 (85.1/14.9%) 35/13 (72.9/27.1%) 0.21
Mean duration of follow-up [months] 12.9 ± 4.0 12.3 ± 3.9 0.46
Age at DCM diagnosis [years] 47 ± 10.6 49.8 ± 11.1 0.21
Time since DCM diagnosis [years] 4.7 ± 3.1 3.9 ± 2.5 0.17
Body weight [kg] 82.8 ± 9 84.3 ± 7.7 0.38
Body weight index [kg/m2] 27.8 ± 4.0 27.9 ± 3.6 0.89
6MWT [m] 297.1 ± 81.3 279.6 ± 84.2 0.31
Familial DCM (1st degree relative) 25/47 (53%) 16/48 (33%) 0.06
Beta-blockers [%] 47/47 (100%) 48/48 (100%) 1.0
ACEI/ARB [%] 46/47 (98%) 48/48 (100%) 0.49
Diuretics [%] 31/47 (66%) 30/48 (63%) 0.83
Spironolactone [%] 40/47 (82%) 39/48 (81%) 0.78
Digoxin [%] 32/47 (68%) 27/48 (56%) 0.29
Long-acting nitrate [%] 28/47 (60%) 25/48 (52%) 0.54
Acetylsalicylic acid [%] 35/47 (75%) 36/48 (75%) 1.0
Vitamin K antagonist [%] 12/47 (26%) 11/48 (23%) 0.81
ATOR(+) — active treatment group; ATOR(–) — control group; 6MWT — 6-minute walking test; ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin receptor blocker
Table 1. Rates of clinical endpoints during one-year follow-up (no 
significant differences between the groups)
Variable ATOR(+) ATOR(–) P
Pacemaker implantation 13 (27.7%) 15 (31.2%) 0.82
Worsening of NYHA class 6 (12.7%) 10 (20.8%) 0.41
Reduced 6MWT distance 14 
(29.8%)
17 (35.4%) 0.66
Cardiac transplantation 3 (6.4%) 4 (8.3%) 1.0
Need for hospital admission 13 (27.7%) 18 (37.5%) 0.38
Death 12 
(25.5%)
11 (22.9%) 0.81
Combined endpoint:
• death
• need for hospital  
admission
• cardiac  
transplantation
20 
(42.5%)
25  
(52.1%)
0.41
ATOR(+) — active treatment group; ATOR(–) — control group; NYHA — New York Heart Association; 
6MWT — 6-minute walking test
}
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Table 3. Cardiovascular risk factor rates in the control group [ATOR(–)] and the active treatment group [ATOR(+)]
Variable [%] ATOR(+) ATOR(–) P
A history of cerebrovascular disease (stroke, aneurysm) 13 (28%) 16 (33%) 0.66
Hypertension 25 (53%) 23 (48%) 0.68
Diabetes type 2 5 (11%) 9 (19%) 0.39
Impaired glucose tolerance 1 (2%) 8 (17%) 0.03
Atrial fibrillation 16 (34%) 22 (46%) 0.29
Smoking 28 (60%) 20 (42%) 0.1
Table 4. Lipid levels at baseline and at 12 months in both groups. Baseline data available for n = 47 in the ATOR(+) group, n = 48 in 
the ATOR(–) group, 12-month data available for n = 35 in the ATOR(+) group, n = 37 in the ATOR(–) group. No significant differences 
(P < 0.05) at 12 months compared to baseline
Variable ATOR (+) ATOR(–) p P’ P”
Total cholesterol [mg/dL]
Baseline 176.1 ± 47.6 187.5 ± 43.8 0.22
0.13 0.54
Change at 12 months –15.9 ± 59.4 6.6 ± 64.6 0.13
HDL cholesterol [mg/dL]
Baseline 45.8 ± 15.3 47.8 ± 15.4 0.53
0.04 0.51
Change at 12 months 6.3 ± 17.7* –2.4 ± 22.0 0.06
LDL cholesterol [mg/dL]
Baseline 106.9 ± 42.1 106.6 ± 35.5 0.97
0.51 0.59
Change at 12 months –9.9 ± 51.5 –3.8 ± 42.7 0.59
TG [mg/dL]
Baseline 141.8 ± 75.6 133.2 ± 64.2 0.55
0.18 0.84
Change at 12 months –24.3 ± 104.1 –2.8 ± 84.5 0.34
p denotes differences between the ATOR(+) and ATOR(–) group during 12-month follow-up; P’ denotes differences between baseline and 12 months in the ATOR(+) group, and P” denotes differences between 
baseline and 12 months in the ATOR(–) group; *significant (P < 0.05) difference at 12 months compared to baseline; ATOR(+), active treatment group; ATOR(–) — control group; HDL — high-density lipoprote-
in; LDL — low-density lipoprotein; TG — triglycerides
Table 5. Distribution of the New York Heart Association (NYHA) functional class in the active treatment group [ATOR(+)] and the control 
group [ATOR(–)] at baseline and at 12 months of follow-up (a significant difference in the NYHA class distribution at 12 months vs. baseli-
ne in the ATOR(+) group, P = 0.03)
Group NYHA class
I II III IV
A ATOR(+) baseline 1/47 (2.1%) 10/47 (21.3%) 29 (61.7%) 7 (14.9%)
B ATOR(+) 12 months 3/35 (8.6%) 16/35 (45.7%) 15/35 (42.9%) 1/35 (2.9%)
C ATOR(–) baseline 0/48 (0%) 13/48 (27.1%) 24/48 (50%) 11/48 (22.9%)
D ATOR(–) 12 months 1/37 (2.7%) 9/37 (24.3%) 24/37 (64.9%) 3/37 (8.1%)
the control group. Lipid levels during the follow-up in both 
groups are shown in Table 4. The baseline values did not 
differ between the atorvastatin and control groups, and 
a significant increase in HDL cholesterol level was found at 
12 months in the atorvastatin group compared to baseline 
which was not seen in the control group.
Table 5 shows the distribution of NYHA class in the 
atorvastatin and control groups during 12 months of fol-
low-up. Atorvastatin treatment was associated with a sig-
nificant improvement in the severity of heart failure during 
12 months of follow-up (P = 0.03). A significant change in 
the NYHA class was noted during 12 months of follow-up 
in favour of the atorvastatin group compared to the control 
group (P = 0.03) (Table 6).
Table 7 shows heart failure parameters during 12 months 
of follow-up and their changes at 12 months in the atorvas-
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groups, a reduction in the level of N-terminal propeptide 
of brain natriuretic peptide (NT-proBNP) and an increase 
in 6MWT distance were noted but these differences were 
not significant.
tatin group compared to the control group. A significant 
reduction in the severity of heart failure symptoms as 
measured by the NYHA class was noted in the atorvastatin 
group which was not seen in the control group. In both study 
Table 6. Change in the New York Heart Association (NYHA) functional class in the active treatment group [ATOR(+)] and the control group 
[ATOR(–)] at 12 months compared to baseline, a significant difference (P = 0.03)
Variable
Group Improvement in NYHA class NYHA Worsening or no change in NYHA class
ATOR(+) 21/35 (70.2%) 14/35 (29.8%)
ATOR(–) 12/37 (47.9%) 25/37 (52.1%)
Table 7. Heart failure parameters in the study groups. Baseline data available for n = 47 in the ATOR(+) group, n = 48 in the ATOR(–) 
group, 12-month data available for n = 35 in the ATOR(+) group, n = 37 in the ATOR(–) group
Variable ATOR(+) ATOR(–) p P’ P”
NYHA class [I–IV]
Baseline 3.0 2.9 0.67
0.01 0.14Change at 12 months 0.6* 0.1 0.02
6MWT [m]
Baseline 297 ± 81 279 ± 84 0.31
0.14 0.37Change at 12 months 11 ± 45.8 1.7 ± 18.4 0.21
NT-proBNP [pg/mL]
Baseline 4741 ± 4531 3925 ± 2354 0.27
0.27 0.19Change at 12 months –904 ± 4762 –674.6 ± 2480 0.79
LA [mm]
Baseline 50.1 ± 7.1 51.4 ± 7.8 0.43
0.06 0.64Change at 12 months –0.5 ± 1.5 0.1 ± 1.0 0.06
LVESD [mm]
Baseline 56.8 ± 9.6 61.3 ± 10.7 0.03
0.0001 0.92Change at 12 months –1.7 ± 2.2* 0.1 ± 5.0 0.05
LVEDD [mm]
Baseline 66.5 ± 8.9 66.0 ± 11.4 0.79
0.003 0.03Change at 12 months –1.2 ± 2.2* –0.6 ± 1.6 0.15
LVESV [cm3]
Baseline 192.6 ± 51.8 190.9 ± 61.8 0.89
0.0001 0.09Change at 12 months –12.4 ± 14.3* –3.4 ± 11.9 0.005
LVEDV [cm3]
Baseline 253.7 ± 64.5 240.3 ± 68.6 0.33
Change at 12 months –11.3 ± 14.8* –3.7 ± 12.4 0.02 0.0001 0.07
LVEF [%]
Baseline 23.9 ± 8.6 21.1 ± 6.5 0.07
Change at 12 months 1.6 ± 2.4* –4.4 ± 9.2 0.002 0.0004 0.93
p denotes differences between the ATOR(+) and ATOR(–) group during 12-month follow-up; P’ denotes differences between baseline and 12 months in the ATOR(+) group, and P” denotes differences between 
baseline and 12 months in the ATOR(–) group; *significant (P < 0.05) difference at 12 months compared to baseline; ATOR(+) — active treatment group; ATOR(–) — control group; NYHA — New York Heart 
Association; 6MWT — 6-minute walking test; NT-proBNP — N-terminal propeptide of the brain natriuretic peptide; LA — left atrium; LVESD — left ventricular end-systolic diameter; LVEDD — left ventricular end-
-diastolic diameter; LVESV — left ventricular end-systolic volume; LVEDV — left ventricular end-diastolic volume; LVEF — left ventricular ejection fraction
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Clinical endpoints during the follow-up
The mean duration of follow-up was 12.6 ± 3.9 months. 
During this time, 23 patients died due to heart failure, in-
cluding 12 patients in the active treatment group (25.5%) 
and 11 patients in the control group (22.9%). The mean 
age of the patients who died vs. those who survived did 
not differ significantly (50.4 ± 13.5 vs. 53.5 ± 11.5 years, 
respectively, P = 0.21). Endpoints noted during one-year 
follow-up are summarized in Table 1.
Another endpoint was the need for hospital admis-
sion due to heart failure worsening. During one-year fol-
low-up, this was required in 31 (32.6%) patients, including 
14 (29.8%) in the active treatment group and 17 (35.4%) 
in the control group (P = 0.66), and the mean time to 
hospital admission in the active treatment group did not 
differ compared to the control group (11.2 ± 4.7 vs. 9.8 ± 
4.6 months, respectively, P = 0.19). A nonsignificant reduc-
tion in the readmission rate by 14% was noted in the active 
treatment group compared to the control group (RR 0.86, 
95% CI 0.65–1.14, P = 0.38). During one-year follow-up, 
atorvastatin treatment was not associated with a signi-
ficant increase in cardiac transplantation-free survival in 
the active treatment group compared to the control group 
(95.6% vs. 91.7%, respectively, P = 0.36).
During 12 months of follow-up, a cardiac resynchro-
nization therapy device was implanted in 28 patients, 
including 13 (27.7%) in the active treatment group com-
pared to 15 (31.2%) in the control group, a nonsignificant 
difference (P = 0.82).
Based on the rates of individual endpoints, we also 
evaluated the rate of a combined endpoint that included 
death, readmission, and the need for heart transplantation. 
This endpoint occurred in 20 (42.5%) patients in the active 
treatment group and in 25 (52.1%) patients in the control 
group, with a nonsignificant reduction in the rate of the 
combined endpoint by 17% (RR 0.83, 95% CI 0.57–1.22, 
P = 0.41).
Echocardiographic parameters
When echocardiographic parameters were evaluated at 
12 months, significant reductions in the left ventricular 
end-systolic dimension (LVESD), left ventricular end-dia-
stolic dimension (LVEDD), left ventricular end-systolic 
volume (LVESV), and left ventricular end-diastolic volume 
(LVEDV) were found in the active treatment group. In ad-
dition, 12-month atorvastatin treatment was associated 
with a significant improvement in LVEF. LVEDD was the 
only parameter which improved significantly at 12 months 
in the control group.
Prognostic parameters
In our study, we identified several clinical predictors of 
mortality during 12 months of follow-up which are shown 
in Table 8. Atorvastatin treatment was not among these 
predictors.
Discussion
Our study is one of few prospective trials of statin treat-
ment in DCM patients. We have not shown a significant 
improvement in short-term outcomes based on the rate 
of clinical endpoints but our data indicate atorvastatin 
treatment may have an effect on the reduction of the se-
verity of heart failure symptoms and beneficial changes in 
echocardiographic parameters.
Multiple studies indicate that cardiomyopathy is the 
end-stage of heart failure developing due to three major 
mechanisms of cardiac damage [6, 9, 13]:
 — genetic — in 20–25% of DCM cases [11], reported 
by Gienner and Battersby in 1961 [12], mostly 
autosomal dominant, less frequently autosomal 
recessive or X-linked [11, 12]. To date, more than 
12 gene deletions were identified [11, 12, 26–29]. 
The proportion of patients with familial DCM in our 
study was 41.5%;
Table 8. Significant (P < 0.05) predictors of mortality in the study group during 12 months of follow-up in univariate analysis
Variable Death (+) 
n = 12
Death (–) 
n = 35
P
Atrial fibrillation 
(yes/no)
1/11 
(8.3/91.6%)
15/20 
(42.9/57.1%)
0.04
Smoking 
(yes/no)
11/1 
(91.6/8.3%)
17/18 
(48.6/51.4%)
0.02
Need for hospital admission  
(yes/no)
7/5 
(58.3/41.6%)
6/29 
(25.7/74.3%)
0.01
Family history  
(yes/no)
1/11 
(8.3/91.6%)
20/15 
(57.1/42.9%)
0.006
Diuretics  
(yes/no)
5/7 
(41.6/58.3%)
26/9 
(74.3/25.7%)
0.04
Heart rate [bpm] 87.3 ± 17.5 73.2 ± 9.3 0.001
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 — immunologic — impaired cellular and humoral immu-
nity manifesting with the presence of specific cardiac 
autoantibodies and an increase in proinflammatory 
cytokines such as tumour necrosis factor α (TNFα) 
which are responsible for systolic dysfunction [26–29];
 — metabolic — obesity is an established cardiovascular 
risk factor. The Framingham Study showed that an 
increase in body mass index (BMI) by 1 kg/m2 is as-
sociated with an increased risk of heart failure (by 5% 
in women and 7% in men), and the risk was increased 
2-fold in obese subjects compared to those with nor-
mal BMI. Another cause of DCM may be longstanding 
diabetes which results in cardiac microangiopathy, 
changes in adipocyte metabolism, cardiac hypertrophy, 
calcium and potassium transport changes, cardiac 
conduction system abnormalities, and reduced sympa-
thetic innervation. Among subjects with DCM, the risk 
of incident heart failure is increased 5-fold in women 
and 2-fold in men.
In our study group, 23 patients (24.2%) died due to 
heart failure over one year, including 12 patients in the 
study group and 11 patients in the control group. Availa-
ble literature data indicate that prognosis in patients with 
clinically overt DCM is poor, with mortality up to 25% at 
one year and 50% at 5 years [14, 24–29]. Our study did 
not show a beneficial effect of atorvastatin on the clinical 
endpoints although a nonsignificant reduction in the end-
point rate was observed and it cannot be excluded that 
these differences might become significant with a longer 
duration of follow-up.
According to the current knowledge, development and 
progression of heart failure depends on neurohormonal 
activation, inflammation, and adaptive changes in the my-
ocardium known as left ventricular remodelling [26–29]. 
These parameters are modulated by the current drug 
treatment of heart failure. Our patients received standard 
guideline-based heart failure treatment, with particular 
attention paid to renin-angiotensin system inhibitors and 
beta-blockers [1, 14]. Our observations during 12 months of 
follow-up in the atorvastatin group (20 mg/day) and the con-
trol group are consistent with the available literature data.
Of note, literature data do suggest a beneficial effect 
of statins on the major pathogenetic mechanisms of heart 
failure [24–29].
In the experimental study by Hayashidani et al. [15], flu-
vastatin was shown to reduce the risk of adverse post-infarc-
tion left ventricular remodelling. Following coronary artery 
ligation, mice received fluvastatin or placebo for 4 weeks. 
Administration of fluvastatin increased survival (61% vs. 
86%, P < 0.05) but had no effect on the extent of post-infarc-
tion scar (52 ± 2% vs. 49 ± 3%, P = NS). Fluvastatin reduced 
post-infarction left ventricular dilatation, end-diastolic left 
ventricular pressure, myocyte hypertrophy, and extracellular 
fibrosis within the non-infarcted area. These data suggest 
that benefits of statin following an acute coronary syndrome 
may be independent from the lipid profile.
Gurgun et al. [16] evaluated the effect of 12-week 
80 mg fluvastatin therapy on the levels of inflammatory 
cytokines and left ventricular function in patients with 
DCM and heart failure due to coronary artery disease, 
with 20 patients recruited into each study group. The study 
showed a significant improvement of left ventricular func-
tion in both patients with DCM (LVEF increase from 30 ± 
5% to 33 ± 5%, P = 0.001) and those with heart failure 
due to coronary artery disease (LVEF increase from 29 ± 
4% to 31 ± 5%, P = 0.01). In addition, clinical symptoms 
of heart failure as evaluated by the NYHA class were re-
duced in both groups. The authors noted that the positive 
effect of statins was probably related to modulation of the 
inflammatory response, which might be of importance in 
our patients. This hypothesis was confirmed in the study 
by Horwich et al. [17] that showed that statin therapy was 
associated with an improved cardiac transplantation-free 
survival during one year of follow-up in patients with both 
ischemic and non-ischemic cardiomyopathy (91% vs. 72%, 
P = 0.001, and 81% vs. 63%, P = 0.001, respectively). 
Improved exercise tolerance measured by NYHA class 
was found in DCM patients treated with simvastatin for 
14 weeks compared to placebo.
The effect of atorvastatin 20 mg daily on vascular in-
flammation parameters and echocardiographic variables 
was evaluated by Sola et al. [18]. The study included 89 pa-
tients with DCM, NYHA class II–IV, and LVEF < 35%. The 
authors reported improved LVESD (53.4 ± 5.1 vs. 60.3 ± 5.1, 
P = 0.01), LVEDD (39.1 ± 3.8 vs. 43.1 ± 4.5, P = 0.01), 
and LVEF (37 ± 4.1 vs. 31 ± 3.1, P = 0.004) in the atorvas-
tatin group compared to placebo. Of note, atorvastatin 
treatment was also associated with an improvement in 
the NYHA class (P = 0.001). The authors concluded that 
atorvastatin might delay adverse myocardial remodelling. 
These observations are in agreement with changes in 
echocardiographic parameters seen in the present study. 
Of note, this effect was not seen with rosuvastatin 10 mg 
daily in the GISSI-HF study [34].
In the Heart Protection Study (HPS) population [19], the 
effect of simvastatin treatment was evaluated in relation to 
the severity of heart failure measured by NT-proBNP levels 
during nearly 5 years of follow-up. The authors showed that 
this treatment reduced the coronary event risk, natriuretic 
peptide levels, and other vascular events.
In the study by Node et al. [20, 21], beneficial effects 
of statins were shown in a group of 51 patients with left 
ventricular systolic dysfunction who were in NYHA class 
II–III. In patients on chronic statin treatment, a clinical im-
provement in heart failure by at least one NYHA class was 
seen, along with an increase in LVEF (from 34 ± 3% to 41 ± 
4%, P < 0.05) [22, 23] and reduced levels of inflammatory 
mediators, interleukin-1 (IL-1), TNFα and brain natriuretic 
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peptide (BNP) [20, 21, 23], which are responsible for ma-
jor pathogenetic processes leading to myocardial systolic 
dysfunction in DCM.
However, these beneficial effects of statins were not 
confirmed in large randomized trials that evaluated the 
effect of statins in heart failure due to ischemic (CORONA) 
or mixed aetiology (GISSI-HF) [35]. Of note, both these 
trials evaluated rosuvastatin 10 mg daily. The COntrolled 
ROsuvastatin multiNAtional trial in heart failure (CORONA) 
study [24] evaluated the hypothesis that benefits of ro-
suvastatin would outweigh possible harms associated 
with this therapy, leading to increased survival, reduced 
symptoms, and reduced mortality in patients with chronic 
symptomatic non-ischemic heart failure. The study included 
patients > 60 years of age with symptomatic systolic heart 
failure (LVEF ≤ 35% if NYHA class II or 40% if NYHA class III/ 
/IV) who previously did not receive lipid-lowering treatment. 
The study included 5011 patients (mean age 73 years, 41% 
patients > 75 years) who were randomly assigned to rosu-
vastatin 10 mg daily (n = 2514) or placebo (n = 2497). The 
mean duration of follow-up was 32.8 months. No baseline 
differences were found between the two groups. Significant 
reductions in low-density lipoprotein (LDL) cholesterol (by 
45%, P < 0.001), high-density lipoprotein (HDL) cholesterol 
(by 5%, P < 0.001), and triglyceride levels (by 20.5%, P < 
0.001) were seen in the rosuvastatin group compared to the 
placebo group. High-sensitivity C-reactive protein (hsCRP) 
level was also significantly reduced by 37.1%. The primary 
endpoint (cardiovascular death, myocardial infarction, or 
stroke) occurred in 692 patients in the rosuvastatin group 
and 732 patients in the placebo group (RR 0.92; 95% CI 
0.83–1.02, P = 0.12). Rosuvastatin had no effect on the 
NYHA class and the rate of incident diabetes (P = 0.40). 
The authors concluded that no mortality reduction with 
rosuvastatin was observed in heart failure patients during 
a 3-year follow-up but the hospital admission rate was sig-
nificantly reduced by about 10% in the rosuvastatin group. 
No differences were found in the rates of admissions due 
to unstable angina and non-cardiac causes. The treatment 
safety analysis did not identify any significant adverse 
effects of rosuvastatin across the many evaluated clinical 
and laboratory parameters.
Of note, significant differences exist between the CO-
RONA study population and our study population. The rates 
of heart failure medication use in the CORONA study were 
similar to our study, with 90% patients on diuretics, 42% 
patients on aldosterone antagonists, 91% patients on ACE/ 
/ARB, 75% patients on beta-blockers and 32% patients on 
digoxin but the major difference was the aetiology of heart 
failure. In our study, we evaluated patients with idiopathic 
DCM, while the patients in the CORONA study had heart 
failure of ischemic aetiology which is associated with worse 
outcomes. Patients in the CORONA study were older, which 
makes it much more difficult to show a beneficial treatment 
effect. Rosuvastatin treatment was not asso ciated with 
a significant reduction in the rate of the primary endpoint 
(RR 0.92; 95% CI 0.83–1.02, P = 0.12), similarly to our 
patients treated with atorvastatin (RR 0.83; 95% CI 0.57– 
–1.22, P = 0.18), although numerically the effect was more 
evident in our study group. Both studies, however, showed 
a reduced hospitalization rate and improved NYHA class in 
the active treatment group.
An important study looking into the effect of statins 
in ischemic heart failure was the analysis of the CORONA 
study by Cleland et al. [30]. The authors hypothesized 
that despite a lack of a protective effect of statins in the 
general heart failure population, an inverse association 
exists between the effect of rosuvastatin and NT-proBNP 
level. Data analysis showed a cut-off NT-proBNP level for 
benefits of rosuvastatin in patients with ischemic heart 
failure, estimated at 868 pg/mL. Thus, statin treatment 
had an effect on the cardiovascular event risk. In patients 
with milder heart failure (NT-proBNP level < 868 pg/mL), 
rosuvastatin treatment was associated with fewer adverse 
clinical events and a 35% reduction in the primary endpoint 
rate (cardiovascular death, myocardial infarction, or stroke, 
P = 0.005), while no such effect was seen in patients with 
higher NT-proBNP levels (> 868 pg/mL). In summary, the 
authors concluded that their analysis supported statin use 
in patients with milder heart failure and coronary artery 
disease. In our study, the above NT-proBNP level criterion 
was met by 5.3% patients with non-ischemic heart failure.
Another study that looked for predictors of beneficial 
effects of statins in heart failure was the study by McMur-
ray et al. [31]. These authors evaluated antiinflammatory 
properties of statins in the context of potential benefits of 
these drugs in patients with heart failure. This analysis in-
cluded the CORONA study participants with ischemic heart 
failure who received rosuvastatin 10 mg daily or placebo. 
The patients were divided into two groups depending on 
their baseline hs-CRP levels, with hs-CRP level < 2.0 mg/L 
in Group I (placebo: n = 779, rosuvastatin: n = 777), and 
hs-CRP level ≥ 2.0 mg/L in Group II (placebo: n = 1694, 
rosuvastatin: n = 1711). The patients were followed up for 
the occurrence of cardiovascular death, myocardial infarc-
tion, and stroke. Median hs-CRP level was higher in Group 
II compared to Group I (5.6 mg/L vs 1.1 mg/L, respectively) 
and associated with worse treatment outcomes. During 
a 3-month follow-up, a nonsignificant 6% reduction in 
hs-CRP level in Group I (27% in the placebo subgroup) and 
a significant (P = 0.024) 33% reduction in hs-CRP level in 
Group II (11.1% in the placebo subgroup) was noted. The 
authors concluded that a beneficial interaction between 
hs-CRP level and the effect of rosuvastatin on the clinical 
endpoint rate was identified, particularly in patients with 
hs-CRP levels ≥ 2.0 mg/L.
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Predictors of a good response to statin therapy were 
also looked for in the study by Gullestad et al. [32] who 
evaluated the efficacy of statin treatment in patients with 
chronic ischemic heart failure in relation to plasma galec-
tin-3 level, a marker of myocardial fibrosis. This analysis 
included 1492 participants of the CORONA study who were 
randomized to rosuvastatin 10 mg daily or placebo. The 
primary endpoint which included cardiovascular death, 
myocardial infarction, and stroke occurred in 411 patients. 
The mean duration of follow-up was 32.8 months. In this 
analysis, a cut-off galectin-3 level of ≤ 19.0 ng/mL was 
identified that was associated with significantly fewer 
clinical adverse effects (HR 0.65, 95% CI 0.46–0.92, P = 
0.014), along with a 30% reduction in all-cause mortality 
and a 28% reduction in the rate of deaths and readmissions 
due to exacerbated heart failure. It was also found that 
a combination of low galectin-3 level and NT-proBNP level 
< 102.7 pmol/L identified patients with particularly large 
rosuvastatin treatment benefits. The authors concluded 
that galectin-3 level of ≤ 19.0 ng/mL was another predictor 
of a good response to rosuvastatin treatment in patients 
with ischemic heart failure.
In another important study that was a subanalysis of 
the CORONA trial data, Rogers et al. [33] evaluated adverse 
clinical events including readmissions due to heart failure. 
The follow-up included 5011 patients, of which 1291 were 
hospitalized at least once due to exacerbated heart fail-
ure (including 750 patients with only one readmission). 
Although the time to the first readmission did not differ 
between the rosuvastatin and placebo groups (HR 0.91, 
95% CI 0.82–1.02, P = 0.105), the risk of readmission 
was reduced by 20% when multiple hospitalizations were 
taken into account. Similar findings were obtained in an 
analysis that included admissions due to all cardiovascular 
causes and all hospitalizations. The authors concluded that 
rosuvastatin treatment was associated with a reduction 
in the annual readmission risk by up to 15–20%, which 
corresponds to the observed NYHA class improvement in 
our study.
Based on these analyses of the CORONA trial data, 
a number of predictors of a good response to statin therapy 
in patients with chronic ischemic heart failure were identi-
fied. Some of them are used in the routine clinical practice 
(NT-proBNP, hs-CRP) while others require further research, 
e.g., galectin-3. Any of these parameters might help predict 
the effect and benefits of statins in these patients.
Study limitations
Our study had a number of limitations. It was a single-cen-
tre, unblinded study but these factors arguably had a less 
important effect on the evaluation of measurable para-
meters and clinical endpoints. The study sample was small 
which was related to the uniform aetiology. Study results 
might have been affected by the fact that the duration of 
follow-up was limited to one year.
Conclusions
Based on the result of our prospective randomized study, 
atorvastatin treatment in patients with idiopathic DCM is 
safe but does not reduce the risk of mortality and major 
clinical endpoints during one year of follow-up. Our findings 
indicate that some beneficial effect on subjective functional 
parameters (NYHA class) and left ventricular remodelling 
may be expected. It cannot be excluded that more bene-
fits could be obtained in other populations during longer 
follow-up.
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Streszczenie
Wstęp. Kardiomiopatia rozstrzeniowa jest chorobą serca charakteryzującą się poszerzeniem i upośledzeniem kurczli-
wości lewej komory lub obu komór. Częstość jej rozpoznań zwiększa się z powodu starzenia się populacji, stosowania 
nowych metod diagnostycznych oraz postępów w farmakoterapii niewydolności serca.
Materiał i metody. W przedstawionym badaniu podjęto próbę określania skuteczności atorwastatyny oraz jej wpływu na 
częstość występowania powikłań klinicznych. Do badania włączono łącznie 95 chorych (47 do grupy badanej i 48 do 
grupy kontrolnej) z kardiomiopatią rozstrzeniową w 2 klasie według New York Heart Association (NYHA). Poza standar-
dowymi lekami zwykle zalecanymi w leczeniu niewydolności serca w badanej grupie (aktywnego leczenia) stosowano 
dodatkowo atorwastatynę w dawce 20 mg/dobę przez rok. Wszyscy pacjenci zostali poddani szczegółowej ocenie kli-
nicznej, elektrokardiograficznej i echokardiograficznej na początku badania i po 12 miesiącach obserwacji.
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Wyniki. W trakcie trwającej 12 miesięcy obserwacji zmarło 23 pacjentów (12 z grupy badanej i 11 z grupy kontrolnej). 
Ponadto w badanej populacji obserwowano zmniejszenie się nasilenia objawów klinicznych (z III do II klasy czynnościo-
wej wg NYHA), zwiększenie wartości przesączania kłębuszkowego oraz poprawę wielu parametrów echokardiograficz-
nych lewej komory).
Wnioski. U pacjentów z idiopatyczną kardiomiopatią rozstrzeniową stosowanie statyn nie wiąże się z poprawą rokowa-
nia, a stratyfikacja średnioterminowego ryzyka jest możliwa na podstawie szczegółowego badania klinicznego, badania 
echokardiograficznego oraz oceny biochemicznej.
Słowa kluczowe: kardiomiopatia rozstrzeniowa, niewydolność serca, klasyfikacja czynnościowa według NYHA,  
echokardiografia
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